January 6, 2009 -- Ark Therapeutics Group plc is pleased to announce today that the Marketing Authorisation Application (MAA) for Cerepro, Ark's novel gene-based therapy for operable malignant glioma (brain cancer) which was recently filed with the European Medicines Regulatory Agency (EMEA), has cleared the validation stage.
The details can be read here.
No comments:
Post a Comment